摘要
局晚期非小细胞肺癌是异质性很强的一类疾病,对于驱动基因阴性不可切除的这部分患者,传统治疗以同步放化疗为主。随着免疫时代的到来,同步放化疗与免疫治疗的综合治疗模式大幅度提升了患者的疗效,并显著延长生存期。本文对放疗、化疗及ICIs在NSCLC治疗中的相互作用机制及临床研究进展进行总结,同时对未来治疗的发展和预测性生物标志物进行展望,为不可切除局晚期NSCLC患者的治疗选择提供参考依据。
Locally advanced non-small cell lung cancer(NSCLC)is a highly heterogeneous disease.For patients with driver gene-negative,unresectable NSCLC,traditional treatment primarily involves concurrent chemoradiotherapy.With the ad-vent of the immunotherapy era,integrated treatment strategies combining concurrent chemoradiotherapy with immunother-apy have significantly improved therapeutic outcomes and substantially extended survival periods.This article summarizes the interaction mechanisms and clinical research progress of radiotherapy,chemotherapy,and immune checkpoint inhibitors in the treatment of NSCLC.This review also provides perspectives on the development of therapies in the future and predict-ive biomarkers,serving as a reference for treatment options for patients with unresectable locally advanced NSCLC.
作者
段琳
代嘉鑫
刘玉龙
DUAN Lin;DAI Jiaxin;LIU Yulong(Department of Oncology,People's Hospital of Manzhouli,Manzhouli 021400,China;Occupational Medicine Department of Nuclear Industry Hospital 417,Xi'an 710600,China;Clinical Cancer Diagnosis and Treatment Center,Second Affiliated Hospital of Soochow University,Suzhou 215004,China)
出处
《中国辐射卫生》
2025年第3期456-462,共7页
Chinese Journal of Radiological Health
基金
国家自然科学基金项目(U2267220)
国家自然科学基金项目(12405392)
江苏省自然科学基金青年项目(BK20240358)
中核集团“青年英才"科研项目(启明星)
省部共建放射医学与辐射防护国家重点实验室开放课题(GZK12024042)
河南省辐射生物与流行病学医学重点实验室课题(HNRBEKF202401)
省部共建放射医学与辐射防护国家重点实验室内部协作课题(GZN1202201)
苏大附二院科研预研基金项目(SDFEYBS2304)。
关键词
局晚期
非小细胞肺癌
免疫检查点抑制剂
同步放化疗
Locally advanced
Non-small cell lung cancer
Immune checkpoint inhibitor
Concurrent chemoradiotherapy
